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Abstract 
In lung vasculature, reversible constriction of smooth muscle cells exists in response to acute 
decrease in oxygen levels (hypoxia). Progressive and irreversible structural remodeling that reduces 
blood vessel lumen takes place in response to chronic hypoxia and results in pulmonary 
hypertension. Several studies have shown a role of serotonin in regulating acute and chronic 
hypoxic responses. In this review the contribution of serotonin, its receptors and transporter in lung 
hypoxic responses is discussed. Hypoxic conditions modify plasma levels of serotonin, serotonin 
transporter activity, and expression of 5-HT1B and 5-HT2B receptors. These appear required for 
pulmonary vascular cell proliferation, which depends on the ratio between reactive oxygen species 
and nitric oxide. A heterozygous mutation was identified in the 5-HT2B receptor gene of a patient 
who developed pulmonary hypertension after fenfluramines anorexigen treatment. This C-terminus 
truncated 5-HT2B mutant receptor presents lower nitric oxide coupling, and higher cell proliferation 
capacity than wildtype receptor. Under low oxygen tension, cells increase the transcription of 
specific genes via stabilization of the transcription factor HIF-1. Factors such as angiotensin II or 
thrombin that can also control HIF-1 pathway, contribute to pulmonary vascular remodeling. The 5-
HT2B receptor via phosphatidylinositol-3 kinase/Akt activates NF-kappaB, which is involved in the 
regulation of HIF-1 expression. A control of HIF-1 by 5-HT2B receptors explains why expression of 
pulmonary vascular remodeling factors, such as endothelin-1 or TGF-beta, which is HIF-1-alpha 
regulated, is not modified in hypoxic 5-HT2B receptor mutant mice. Understanding the detailed 
mechanisms involved in lung hypoxic responses may provide general insight into pulmonary 
hypertension pathogenesis.  
 
 
Keywords: Arteries; Cell Division; Dexfenfluramine; Hypoxia; Physiopathology; Pulmonary 
Hypertension; Receptor; Serotonin; Transporter; Vascular Remodeling. 
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Introduction 
Aerobic evolution has resulted in mammalian cells and tissues metabolism that is oxygen-
dependent. At normal O2 tension, oxidative phosphorylation is the principal energy supply for 
eukaryotic cells but at low O2 tension, metabolic switches turn off mitochondrial electron transport 
and activate anaerobic glycolysis. Maintenance of normal tissue function thus depends on a 
continuous supply of O2, so it is crucial that the body detects and responds rapidly to hypoxia (1). 
The vascular system responds to acute hypoxia in several ways. In the systemic arterial system, 
acute hypoxia causes vasodilatation; in pulmonary arteries, however, it elicits reversible 
vasoconstriction (2). Unlike acute hypoxia, in response to chronic hypoxia, pulmonary vasculature 
remodeling (PVR) takes place upon persistent vasoconstriction, resulting in reduced blood vessel 
lumen diameter, increased resistance. This persistent vasoconstriction, when permanent becomes 
irreversible and causes pulmonary hypertension (PH) (3). PVR results from alterations of the 
balance between the effects of vasodilators and antiproliferative agents produced by the 
endothelium (e.g., prostacyclin and nitric oxide (NO⋅), and vasoconstrictors and mitogenic factors 
(e.g., endothelin-1, endothelium-derived growth factor, and 5-HT) (4-6). Understanding the 
mechanisms underlying irreversible PVR is an important step in defining therapeutic targets, since 
many known pulmonary vasodilators diminish pulmonary remodeling by reducing pulmonary 
pressure (7, 8), and remodeling of the walls of distal pulmonary arteries is common in secondary 
and primary PH (9).  
 Serotonin (5-hydroxytryptamine, 5-HT) mediates myriad functions in the nervous and 
vascular systems. In the central nervous system, 5-HT is synthesized by neurons in the raphe 
nucleus; in the periphery, 5-HT is produced by the enterochromaffin cells of the gut. The actions of 
5-HT are mediated by four receptor classes: ligand-gated cation channels (5-HT3 receptors) and 
three groups of G protein-coupled receptors (5-HT1/5, 5-HT2, 5-HT4/6/7), each of which exhibits 
coupling to different in G proteins (10). The 5-HT1/5 receptor (5-HT1R) subfamily has 7 members 
(5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F, 5-ht5A, and 5-ht5B) that are negatively coupled to adenylyl 
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cyclase via pertussis toxin-sensitive Gi/o proteins, leading to decreases in intracellular cAMP. The 5-
HT2R subfamily comprises 3 members (5-HT2A, 5-HT2B, and 5-HT2C) that are positively coupled to 
phospholipase C (PLC) via Gq/11 proteins, leading to increases in intracellular inositol 1,4,5-
trisphosphate (IP3), 1,2-diacylglycerol (DAG) and Ca2+. The 5-HT4, 5-HT6, and 5-HT7Rs are 
positively coupled to adenylyl cyclase via cholera toxin-sensitive Gs proteins, leading to increases 
in intracellular cAMP. 
 Several studies have demonstrated a role for 5-HTRs in regulating hypoxic responses. For 
instance, in the pond snail Helisoma trivolvis, a decrease in environmental O2 levels after 
gastrulation stimulates cilia-mediated rotational movements of the embryo; this hypoxia-induced 
response is mediated by two serotonergic sensory-motor neurons that both detect reduced O2 levels 
and activate ciliary movements (11). Also, intermittent hypoxia causes a long-term facilitation 
(LTF) of respiratory motor output; this neural plasticity requires 5-HT1A, 5-HT1B, and 5-HT2Rs (12). 
Furthermore, chronic hypoxia enhances LTF-evoked responses to intermittent hypoxia; this 
metaplasticity is mediated by 5-HT2 and 5-HT6 and/or 5-HT7Rs (13). Different chemosensory 
organs such as the carotid bodies (CB) and pulmonary neuroepithelial bodies (NEB) respond to 
hypoxia in a serotonin-dependent fashion. CB type I cells contain 5-HT and express 5-HT1A, 5-HT3, 
and 5-HT5ARs that affect CB function when arterial pO2 is reduced (14). NEBs release 5-HT in 
response to acute hypoxia by a mechanism involving the 5-HT3R (15). Unlike hypoxic responses in 
the nervous system, which involve many different 5-HTR subtypes, hypoxia-induced 
vasoconstriction in the pulmonary vasculature appears to involve only 5-HT1 and 5-HT2Rs. In 
recent years, several studies have demonstrated that 5-HTRs control hypoxic responses in the 
pulmonary vascular system (16). The exact pathways through which hypoxia causes 
vasoconstriction and pulmonary vascular remodeling (PVR) are just beginning to be identified. 
What is clear, however, is that hypoxia alters molecular (e.g., protein expression) and cellular (e.g., 
proliferation) processes via mechanisms that involve serotonin, its receptors, and its transporter to 
elicit the physiological, pulmonary responses to hypoxia (vasoconstriction and PVR). In this 
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review, we will highlight the current understanding of the serotonin-dependent mechanisms 
underlying pulmonary hypoxic responses. 
 
1. Regulation by 5-HT of hypoxia-induced PVR 
 1.1. Hypoxic conditions modify 5-HT levels 
The function of 5-HTRs in hypoxic responses in the pulmonary vasculature must be 
dependent on the presence of suitable 5-HT levels activating these receptors. In healthy subjects, 
unconjugated plasma 5-HT levels are low (<10 nM); however, in PH patients, plasma 5-HT is 
consistently elevated (17-19). A deficiency in platelet 5-HT storage, as is characteristic of Fawn 
hooded rats, contributes to the development of severe PH under both normoxic (20) and hypoxic 
(high altitude) (21) conditions. These observations suggest an etiological role for 5-HT in the 
development of PH and raise two important questions: 1) what is the source of 5-HT in the 
pulmonary vasculature, and 2) how does reduced O2 lead to an increase in plasma 5-HT levels?  
 In the periphery, 5-HT is synthesized and secreted from neuroendocrine enterochromaffin 
cells in the gut. 5-HT is mainly eliminated by uptake in lung endothelial cells, where it is then 
degraded by MAO (22). Platelets take up 5-HT through the 5-HT transporter (5-HTT) and store—
but only slowly degrade—the monoamine. Former studies have shown that long-term hypoxia 
causes decreased platelet counts and short-term hypoxia increased platelet counts (23). Later, it has 
been established that chronic hypoxia, a stimulator of erythropoiesis, causes thrombocytopenia in 
laboratory animals. The thrombocytopenia is most likely the result of a reduction in the production 
of platelets caused by a decrease in the number of megakaryocytes in the bone marrow. The 
thrombocytopenia seems to be caused by competition of a precursor cell of the erythrocytic and 
megakaryocytic cell lines (24). Moreover, hypoxia facilitates platelets aggregation (25). Alteration 
of platelet number and/or function under hypoxic conditions could thus concertedly reduce 5-HT 
uptake and would explain hypoxia-induced increases in circulating plasma 5-HT. In this regard, 
platelet activation was found in the pulmonary vessels of patients with PH secondary to chronic 
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obstructive pulmonary disease (26), and platelet survival time is reduced in patients with hypoxemia 
and PH (27). Anti-platelet agents, such as dipyridamole, reduce hypoxemic PH and the thickness of 
pulmonary arteries in response to chronic hypoxia (28). Based on these results, it has been 
postulated that circulating plasma 5-HT may originate from platelets (29).  
 Pulmonary NEB also secrete 5-HT in response to airway hypoxia (15). In this way, cellular 
and molecular hypoxia-regulated mechanisms, which have an effect on circulating plasma 5-HT 
levels, probably involve platelets and pulmonary NEB, as well as reductions in the lungs’ ability to 
uptake and/or remove 5-HT. The 5-HT2ARs have been detected in platelets (30, 31), where they 
enhance platelets aggregation (25). The activation of presynaptic 5-HT1B/1DR decreases 5-HT release 
(32), and in neonatal rabbit pulmonary NEB, 5-HT3Rs are involved in a positive feedback loop 
resulting in hypoxia-induced 5-HT release (15). Together these observations suggest that 5-HT 
receptors control plasma levels of their ligand in response to hypoxia. 
 1.2. Putative role of 5-HTT in the hypoxic PVR 
In recent years, many studies have explored the possible role of 5-HTT in hypoxia-induced 
PVR. Hypoxia causes changes in 5-HTT expression: acute and chronic hypoxia increase 5-HTT 
mRNA levels in rat pulmonary arteries (33). Upon acute hypoxia, specific 5-HT transport is 
increased in porcine pulmonary artery endothelial cells without a concomitant increase in Km; Acute 
hypoxia (i) results in an elevation of the maximal uptake rate (Vmax), implying de novo protein 
synthesis, and (ii) modifies plasma membrane phospholipids and consequently its fluidity (34). 
Conversely, chronic hypoxia reduces 5-HT uptake by pulmonary arteries (35).  
 In rat pulmonary artery SMC, 5-HT induces DNA synthesis, and acute hypoxia potentiates 
this mitogenic effect. The increase in DNA synthesis can be prevented by high concentrations of 5-
HTT inhibitors (36). In mice, increased PVR as a result of exposure to chronic hypoxia is partially 
reduced by the 5-HTT inhibitors citalopram and fluoxetine (37). Nonetheless, in sodium-free 
conditions (i.e., without 5-HT uptake), 5-HTT inhibitors still attenuated 5-HT-induced mitogenesis 
(38). Importantly, some 5-HTT inhibitors (including citalopram and fluoxetine) have µM affinities 
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for 5-HT2R (39). Recent results indicate that there is synergy between the inhibitory effects of 5-
HT1BR antagonists and 5-HTT inhibitors on 5-HT-induced pulmonary vasoconstriction (40) and that 
nordexfenfluramine (NorDF)-induced vasoconstriction is not dependent on 5-HTT-mediated release 
of endogenous 5-HT but rather via direct activation of 5-HTRs (41). These observations suggest 
that 5-HT uptake by 5-HTT cannot fully account for the proliferative action of 5-HT, and support a 
role for 5-HTRs. The proposition that the long 5-HTT promoter polymorphism promotes PVR 
through increased 5-HTT expression does not fully explain why patients who develop PH after 
dexfenfluramine (DF) treatment have the same proportion of this polymorphism as do PH patients 
in general (42) (Launay unpublished). Moreover, the report that PVR after chronic hypoxia is 
reduced—but not completely abolished—in mice deficient for 5-HTT gene (43) demonstrates that 
5-HTT does not solely mediate hypoxia-induced PVR.  
 1.3. Regulation of hypoxia-induced PVR by 5-HTRs 
Different mechanical factors have been shown to induce PVR. Chronic hypoxia can 
stimulate PVR directly and/or by a persistent vasoconstriction process as already suggested (44). 
Despite sustained hypoxia, vasoconstriction persists but subsides somewhat as PVR progresses (7). 
Neurohumoral factors such as 5-HT/5-HTRs may be implicated. 
 The 5-HT1BR-mediated contractile response to 5-HT or 5-carboxamidotryptamine is 
increased in pulmonary arteries isolated from chronic hypoxic wild-type mice. However, the 
activity of 5-HT1BR does not seem to be limiting, as 5-HT1BR knockout mice still respond to 
hypoxia but develop less severe PH and PVR than do wild-type mice (45). Discordantly, Marcos et 
al. report that chronic hypoxia (10% O2 for 2 weeks)-induced pulmonary hypertension and 
increased vessel muscularization were not reduced by the 5-HT1B/1DR antagonist GR127935 (37). 
Thus, the role of 5-HT1BR in hypoxia-induced PH and PVR remains unclear and may be species- 
or strain-sensitive. 
 In ovine common carotid arteries, despite altering the contractile response, acute hypoxia 
had no effect on 5-HT2AR coupling to IP3 second-messenger production (46). Similarly, acute 
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hypoxia reduced 5-HTR density and agonist affinity in adult bovine common carotid arteries (47). 
However, the role of 5-HT2AR in hypoxia-induced PH and PVR is not clear, since the receptor’s 
expression is not modified in the lung vasculature of mice exposed to 10% O2 for 5 weeks (48). 
Furthermore, in mice, the effects of chronic hypoxia on pulmonary artery pressure and vessel 
muscularization are insensitive to the 5-HT2AR antagonist ketanserin (37).  
 Interestingly, mice with pharmacologically or genetically inactive 5-HT2BR do not develop 
PH and PVR following chronic hypoxia, even though the acute hypoxic response (vasoconstriction) 
is intact (48). Therefore, the 5-HT2BR is a key factor in the molecular signaling pathways that 
couple chronic hypoxia to PH and PVR, a pathway independent of acute hypoxia-induced 
vasoconstriction. The 5-HT2BR also functionally interacts with the 5-HT1BR and the 5-HTT, whose 
roles in PH and PVR are rather well established. For instance, 5-HT1BR and 5-HTT activities are 
modulated by 5-HT2BRs (29, 49). Similarly, MacLean proposed a functional interaction between Gi-
coupled (5-HT1BR) and the 5-HT transporter, which would facilitate the development of PH (40). In 
addition, 5-HTT, 5-HT1BR, and 5-HT2BR are colocalized in pulmonary arteries, and 5-HT2BR has 
been reported to regulate 5-HTT activity in the 1C11 serotonergic cell line (50). The emerging 
question, then, is how 5-HTRs control hypoxia-induced PVR. 
 1.4. Possible mechanisms relating vascular injuries to 5-HTRs 
Hypoxia changes levels of reactive oxygen species (ROS) and NO⋅ in the pulmonary 
vascular wall, and these alterations are involved in PVR (51). ROS and NO⋅ levels are sensitive to 
5-HTR activity. For example, 5-HT1BRs and 5-HT2BRs have been shown to increase NO⋅ levels in 
human coronary artery endothelial cells (52), and and to elicit relaxation in porcine pulmonary 
arteries via the release of NO (53). In addition, the 5-HT2AR induces NO⋅ release by regulating 
gastrointestinal transit in mice (54), but can inhibit cytokine-stimulated inducible NO⋅ synthase in 
C6 glioma cells (55). In the cerebral vasculature, NO⋅ release from endothelial cells occurs 
following activation of 5-HT2BRs (56). In several cell lines, 5-HT2BRs have been shown to activate 
both constitutive and inducible NO⋅ synthases via interactions requiring the receptor’s C-terminal 
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PDZ binding domain (57). In this way, 5-HT2BR activity leads to NO· generation both in vitro and 
in vivo. 
 In renal mesangial cells, 5-HT2AR activation induces ROS (e.g., H2O2 and superoxide) 
production via an NAD(P)H oxidase-like enzyme (58). In the hippocampus of mice lacking the 5-
HTT, increased DNA oxidation has been observed, suggesting that the transporter serves as an anti-
oxidant. However, 5-HTT null mice do not exhibit alterations in glutathione (GSH), oxidized 
glutathione (GSSG), and other anti-oxidant systems (59). Recently it has been reported that 5-
HT2BR activation can also induce ROS production by a NAD(P)H oxidase-dependent mechanism in 
a serotonergic cell line (60). The mitochondrial electron transport chain is a major ROS source, and 
mitochondria are a target of 5-HT2BR anti-apoptotic signaling in cardiomyocytes (61). Thus, 5-
HT2BR signaling leads to changes in both NO· and ROS production.  
 1.5. Mutation in 5-HT2BR gene and PH in human exposed to DF 
Recently, by investigating the 5-HT2BR gene in patients who developed pulmonary 
hypertension after intake of DF, a heterozygous mutation was found in one female patient who 
followed a nine-month anorexigen regimen (62). The polymorphism, R393X, results in a truncation 
of the receptor’s C-terminal tail, thus removing (i) putative palmitoylation and phosphorylation sites 
essential for internalization, and (ii) the PSD-95, Dlg, ZO-1 (PDZ) binding motif involved in the 
coupling to NOS and other scaffold proteins. Functionally, the R393X 5-HT2BR exhibits a loss of 
rapid internalization compared to the wild type receptor, a finding consistent with removal of C-
terminal determinants of receptor trafficking (63). In addition, the R393X 5-HT2BR displays 
diminished coupling to NOS compared with the wild type receptor, as expected from removal of the 
PDZ binding motif. Despite the apparent losses of function due to the R393X polymorphism, the 
truncated 5-HT2BR variant displays striking gain of function vis-à-vis proliferative capacity, an 
effect that appears to result from a switch from wild type dual Gq/G13 coupling to a nearly exclusive 
G13 coupling. Thus, given the role of cell proliferation in PH and PVR, the R393X 5-HT2BR 
polymorphism is clearly relevant for vascular proliferation and remodeling (63). The α subunit of 
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G13 plays a critical role in 5-HT2BR-NOS coupling, (63) and G13 has been reported to activate 
inducible NOS through a mechanism distinct from that other Gα isoforms (64). Src family kinases 
(effectors of 5-HT2BRs) (65) act upstream of the small G-protein Rho in G12/13-induced JNK 
activation (66). RhoA and its effector Rho kinase play a major role in the effects of both acute and 
chronic hypoxia on the pulmonary circulation, possibly by modulating both vasoconstriction and 
vascular remodeling (67). The increased G13 coupling displayed by the R393X 5-HT2BR likely 
renders the polymorphism relevant to pathological vasoconstriction and remodeling in response to 
chronic exposure to DF (Fig. 1). 
 
2. Control of hypoxia-dependent transcription by 5-HT 
Under low oxygen tension, cells increase the transcription of genes involved in 
angiogenesis, erythropoiesis, and glycolysis.  
 2.1 Transcriptional regulation of 5-HT-related molecules 
Hypoxia causes transcriptional regulation of both the 5-HTT and 5-HTRs. For example, 5-
HT1BR and 5-HT2BR mRNA levels are increased in the lung vasculature of mice exposed to chronic 
hypoxia (68), while 5-HT2AR expression is unaffected (48). Rat 5-HTT mRNA expression is 
stimulated in proximal pulmonary arteries and lungs upon chronic hypoxia (33). In humans, DF use 
for periods greater than three months is associated with an increased risk for developing PH (6, 69). 
DF, a known substrate of 5-HTT, is metabolized in vivo by N-de-ethylation in norDF, which is a 
potent and selective 5-HT2BR agonist (70, 71). While DF does not trigger PH in mice after 5 weeks 
under normoxic conditions, administration of the drug does potentiate hypoxia-induced PH, (48) 
suggesting that hypoxia (like norDF) acts directly on 5-HTRs to contribute to their actions in the 
pulmonary vasculature. Together, these observations raise the question whether increased 
expression of 5-HTRs is a prerequisite for PVR, and/or if elevation of 5-HT levels and subsequent 
activation of basal 5-HTRs can induce PVR in absence of a hypoxic stimulus.  
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 2.2 Regulation of cell proliferation by 5-HT molecules 
Hypoxia-induced pulmonary artery vascular cell proliferation triggers PVR, which increases 
pulmonary artery pressure (72). In vitro, phenotypically distinct SMC subpopulations in the media 
of bovine main pulmonary artery display differential proliferative responses under extreme hypoxic 
(3% O2 during 72 hours) conditions: DNA synthesis is increased only in a subset of the medial 
subpopulations (73). In bovine and rat pulmonary artery SMC, 5-HT induced DNA synthesis (74), 
and 24 hours under hypoxic conditions can potentiate 5-HT’s mitogenic effect (33). Serotonin 
causes proliferation of many cell types in culture, including vascular SMC, via not only 5-HTRs but 
also through crosstalk with other signal transduction systems, such as the receptors for the growth 
factors platelet-derived growth factor (PDGF), fibroblast growth factor, and epidermal growth 
factor (75). Hypoxia inhibits the release of anti-mitogenic factors such as prostacyclin in cultured 
pulmonary artery endothelium (76). The absence of hypoxia-induced thymidine incorporation (a 
measure of cell proliferation) and vascular muscularization in the lungs of hypoxic 5-HT2BR-/- mice 
indicates an absolute requirement for 5-HT2BR in chronic hypoxia-induced mitogenesis. Further 
demonstrating the key role of 5-HT2BRs in hypoxia-induced mitosis is the finding that the highly 
selective 5-HT2BR antagonist RS-127445 abrogates proliferation and PVR in wild-type mice 
exposed to hypoxia (48).  
 Activation of MAPK, another mediator of proliferative signals, has also been implicated in 
PVR (44). PDGF causes proliferation in pulmonary arterial SMC (77) and increased expression of 
PDGF has been reported in rat lungs subsequent to hypoxic PH (78). In mouse fibroblast LMTK- 
cells stably expressing murine 5-HT2BRs, 5-HT-induced receptor activation leads to cell cycle 
progression via a complex signaling pathway in which the cytoplasmic tyrosine kinase c-Src 
controls cyclin E expression and, in concert with PDGF receptor transactivation, induces cyclin D1 
expression in a MAPK-dependent fashion (65). 
 In sheep with hypoxia-induced PH, increased mRNA levels of the transforming growth 
factor-β (TGF-β) have been associated with PVR (79). It has been suggested that interleukins (ILs) 
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and tumor necrosis factor (TNF)-α are also involved in the development of PVR: serum 
concentrations of IL-1 and IL-6 are increased in patients with primary PH (80); IL-1 is a mitogenic 
factor in human and rat vascular SMC (81); hypoxia stimulates IL-1 production in human vascular 
SMC (82), and NF-IL6 activates IL-6 gene transcription in hypoxic pulmonary vascular endothelial 
cells (83). Chronic hypoxia (10% O2 for 5 weeks) also causes increased TGF-β levels lung vessel 
culture supernatants via a mechanism that requires 5-HT2BR activity (48). The release of TNF-α, 
IL-1β, and IL-6 in response by isoproterenol-treated cardiac fibroblasts is also 5-HT2BR-dependent 
(84). 
 Matrix metalloproteinases (MMPs) activation and extracellular matrix (ECM) remodeling 
contribute to hypoxia-induced pulmonary vascular proliferation in PVR. Some of the best 
characterized ECM substrates for MMPs are collagens, elastin, and proteoglycans (9). An increase 
in elastase activity leads to the release of latent growth factors (85) and elastase activity is increased 
in mice with chronic hypoxia-induced PH (86), an effect that is absent upon genetic or 
pharmacological ablation of 5-HT2BRs (48). These observations suggest that 5-HT2BR-dependent 
elastase activity leads to latent growth factor release including TGF-β. In addition, collagenolytic 
activity in extracts from pulmonary arteries in rats exposed to hypoxia is increased (87) that may 
include MMP activity contributing to PVR. A possible role for 5-HT2BR in the activation of various 
MMPs in PVR is likely, given that activation of MMP-2 (ECM substrates: various collagens, 
fibronectin, laminin, aggrecan, insoluble elastin) and MMP-9 (ECM substrates: various collagens) 
is regulated by 5-HT2ARs in uterine tissue (88) and by 5-HT2BRs in cardiac fibroblasts (LM 
unpublished). Recently, the 5-HT2BR was shown to stimulate TNF-α converting enzyme in a 
serotonergic cell line (60). Thus, 5-HT2R appears to be crucial for hypoxia-induced PVR via MMP-
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3. Regulation of transcription factors expression by 5-HT molecules 
Hypoxic transcription processes are coordinately regulated by the hypoxia-inducible factor 
HIF-1, which, despite its constitutive expression, is only active in response to reduced O2 levels 
(89). Several line of experimental evidence support the hypothesis that factors controlling HIF-1 
expression also contribute to hypoxia-induced PVR. Indeed, a strong correlation has been found 
between HIF-1α overexpression and immunoreactivity of the cell proliferation index Ki67 (90). 
Though hypoxia is the ubiquitous inducer of HIF-1α, other stimuli, such as insulin, insulin-like 
growth factors 1 and 2, and EGF, also increase HIF-1α protein levels in some cells. These stimuli 
also induce VEGF expression in an HIF-1-dependent manner.  
 3.1 Putative regulation of HIF molecules by 5-HT 
The O2-regulated transcription factor HIF-1 has been proposed to control the expression of 
several agents involved in PVR, such as endothelin-1 and TGF-β (91). HIF-1α hypomorphic mice 
develop less severe medial wall thickening in the pulmonary arterioles than do wild type mice 
maintained for 3 weeks at 10% O2 (92). Other factors, such as angiotensin II (Ang II), thrombin, 
platelet-derived growth factor, can increase HIF-1α in vascular SMC to levels beyond those 
resulting from hypoxic treatment. The non-hypoxic induction of the HIF-1 transcription factor via 
vasoactive hormones (Ang II and thrombin) is triggered by a dual mechanism, i.e., PKC-mediated 
transcriptional activation and ROS-dependent increases in HIF-1α protein expression (93). In 5-
HT2BR-expressing cells, receptor activation increases the activity of the c-Src family tyrosine kinase 
and ROS levels through NAD(P)H oxidase (60, 65), which can thus induce HIF-1α expression.  
 3.2 Hypoxia-induced NF-κB expression by 5-HT2BRs 
In cardiomyocytes, 5-HT2BRs, via phosphatidylinositol-3 kinase/Akt, activate NF-κB, an 
event that is required for the receptors’ anti-apoptotic effects (61). Activation of NF-κB is sufficient 
to suppress cell death of ventricular myocytes during hypoxia. Additionally, NF-κB averts cell 
death through a mechanism that prevents perturbations to the mitochondrion during hypoxic injury 
(94). Moreover, the 5-HT2BR has recently been identified in a large-scale screen for human genes 
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that activate NF-κB signaling pathways (95). Furthermore, treatment with LY294002 (a selective 
inhibitor of phosphatidylinositol 3-kinase) significantly inhibits erythropoietin protein and mRNA 
expression in Hep3B cells exposed to hypoxia for 24 hours. Inhibition of NF-κB with a super-
repressor (dominant negative IκBα) also significantly blocks HIF-1 transactivation, as well as 
erythropoietin gene expression 129. We propose that 5-HT2BR expression, which is increased under 
hypoxic conditions, is a trigger of HIF-1α via phosphatidylinositol-3 kinase/Akt/NF-κB pathway. 
 3.3 Hypoxia-induced NF-κB may regulate HIF expression  
Putative control of HIF-1 by 5-HT2BRs would explain why the expression of PVR-inducing 
factors, such as endothelin-1 and TGF-β (both of which are HIF-1-regulated), is not modified in 
hypoxic 5-HT2BR-/- mice. A recent study by Moncada’s group (96) showed that upon hypoxia, 
inhibition of mitochondrial respiration by NO⋅ leads to a redistribution of intracellular O2 toward 
other O2-dependent targets, such as prolyl hydroxylase, which causes the constitutive degradation of 
HIF-1α. Stimulation of the NO/PKG pathway in rats treated with sildenafil increases RhoA protein 
levels, phosphorylation, and association with RhoGDI in the pulmonary artery, effects opposite to 
those induced by chronic inhibition of NO⋅ synthesis or hypoxia. The observed NO⋅ alterations in 
the hypoxic pulmonary vascular wall lead to a plausible explanation for the absence of hypoxia-
induced PVR in 5-HT2BR-/- mice and further strengthen the hypothesis that 5-HT2BR expression 
under hypoxic conditions is not a target but a trigger of HIF-1 (Fig. 3). 
 
Pressing Questions 
Determining of the contribution of 5-HT to hypoxic responses in lung endothelial cells, 
smooth muscle cells, and fibroblasts is of major importance. How and when do these different cell 
types participate in the development and/or progression of PH? Of particular interest is the origin of 
the process. Do normoxic endothelial, fibroblast, and /or smooth muscles cells respond to 5-HT in a 
similar way as hypoxic cells? When does irreversible commitment to hypoxia-induced PVR occur? 
Given that most studies have focused on lung vasoconstrictive factors, how closely does 
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development of the pathology follow that of vasoconstriction? Finally, is the developmental 
program that generates lung vessels in the embryo retained in the lung vasculature of the adult? Is 
this program reactivated in adult lung pathophysiology? The answers to these questions will provide 
general insights into the pathogenesis of PH and may suggest novel therapeutic approaches to 
treating lung diseases in humans. 
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Figure 1. 5-HT in hypoxia-induced PVR. Hypoxia raises 5-HT levels by operating at 
platelets and pulmonary NEB, which acts at 5-HT2BR, 5-HT1BR and 5-HTT. Changes in ROS and 
NO⋅ levels upon hypoxia, result in endothelium and vascular SMC oxidative damage and death. 
ProPVR agents, such as endothelin-1 and TGF-β, have no effect on PVR in the absence of 5-
HT2BRs. Lines with arrows indicate positive actions and with a T negative effects. 
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Figure 2. 5-HT-stimulated transcription pathways in the regulation of hypoxia-induced PVR. 
By controlling 5-HT levels, hypoxia has effects on transcriptional and post-transcriptional control 
of growth factors, via proteinases, which participate in ECM maintenance, leading to PVR. 
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Figure 3. 5-HT2BR-induced transduction pathways relevant to pulmonary hypertension. 
Different experimental evidences support a model in which ROS and NO⋅ can be controlled by 5-
HT2BR that would result in transcriptional activation of cell cycle and hypoxic responses.  
 
